{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:41:46Z","timestamp":1776091306221,"version":"3.50.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T00:00:00Z","timestamp":1639008000000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Allergy Asthma Clin Immunol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Refractory status asthmaticus is the cause of rare cases of in-hospital death due to acute bronchial asthma. The most severe cases unresponsive to first, second and next line treatment may be fatal despite aggressive organ support with invasive ventilation and extracorporeal membrane oxygenation. Omalizumab, a humanized recombinant monoclonal anti-IgE antibody, is an approved add-on biological treatment for severe asthma. However, it is not indicated in an acute setting. Here, we report the case of a young patient with status asthmaticus fully dependent on extracorporeal membrane oxygenation refractory to any therapy for six days, who was successfully treated with omalizumab.<\/jats:p>","DOI":"10.1186\/s13223-021-00629-z","type":"journal-article","created":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T12:07:21Z","timestamp":1639051641000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Successful treatment of refractory status asthmaticus with omalizumab: a case report"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9029-8765","authenticated-orcid":false,"given":"Jan","family":"Benes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman","family":"Skulec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalibor","family":"Jilek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ondrej","family":"Fibigr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Cerny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,9]]},"reference":[{"issue":"10098","key":"629_CR1","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/S0140-6736(17)31448-4","volume":"390","author":"S Ebmeier","year":"2017","unstructured":"Ebmeier S, Thayabaran D, Braithwaite I, B\u00e9namara C, Weatherall M, Beasley R. Trends in international asthma mortality: analysis of data from the WHO Mortality Database from 46 countries (1993\u20132012). Lancet. 2017;390(10098):935\u201345. https:\/\/doi.org\/10.1016\/S0140-6736(17)31448-4.","journal-title":"Lancet"},{"issue":"9","key":"629_CR2","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.3390\/JCM8091283","volume":"8","author":"E Kostakou","year":"2019","unstructured":"Kostakou E, Kaniaris E, Filiou E, Vasileiadis I, Katsaounou P, Tzortzaki E, Koulouris N, Koutsoukou A, Rovina N. Acute severe asthma in adolescent and adult patients: current perspectives on assessment and management. J Clin Med. 2019;8(9):1283. https:\/\/doi.org\/10.3390\/JCM8091283.","journal-title":"J Clin Med"},{"issue":"6","key":"629_CR3","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1164\/AJRCCM.155.6.9196082","volume":"155","author":"JV Fahy","year":"1997","unstructured":"Fahy JV, Fleming HE, Wong HH, Liu JT, Su JQ, Reimann J, Fick RB, Boushey HA. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med. 1997;155(6):1828\u201334. https:\/\/doi.org\/10.1164\/AJRCCM.155.6.9196082.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"629_CR4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","volume":"60","author":"M Humbert","year":"2005","unstructured":"Humbert M, Beasley R, Ayres J, Slavin R, H\u00e9bert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy Eur J Allergy Clin Immunol. 2005;60(3):309\u201316. https:\/\/doi.org\/10.1111\/j.1398-9995.2004.00772.x.","journal-title":"Allergy Eur J Allergy Clin Immunol"},{"issue":"9","key":"629_CR5","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-154-9-201105030-00002","volume":"154","author":"NA Hanania","year":"2011","unstructured":"Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, Rosen KE, Eisner MD, Wong DA, Busse W. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011;154(9):573\u201382. https:\/\/doi.org\/10.7326\/0003-4819-154-9-201105030-00002.","journal-title":"Ann Intern Med"},{"issue":"11","key":"629_CR6","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/nejmoa1009705","volume":"364","author":"WW Busse","year":"2011","unstructured":"Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH, Gruchalla RS, Kattan M, Teach SJ, Pongracic JA, Chmiel JF, Steinbach SF, Calatroni A, Togias A, Thompson KM, Szefler SJ, Sorkness CA. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 2011;364(11):1005\u201315. https:\/\/doi.org\/10.1056\/nejmoa1009705.","journal-title":"N Engl J Med"},{"issue":"5","key":"629_CR7","doi-asserted-by":"publisher","first-page":"351","DOI":"10.7326\/L18-0359","volume":"170","author":"K Milger","year":"2019","unstructured":"Milger K, Schroeder I, Behr J, Meis T, Wulffen WV, Kneidinger N. Omalizumab rescue therapy for refractory status asthmaticus. Ann Intern Med. 2019;170(5):351\u20132. https:\/\/doi.org\/10.7326\/L18-0359.","journal-title":"Ann Intern Med"},{"key":"629_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jaci.2009.02.016","volume":"123","author":"TB Casale","year":"2009","unstructured":"Casale TB, Stokes J. Anti-IgE therapy: clinical utility beyond asthma. J Allergy Clin Immunol. 2009;123:4. https:\/\/doi.org\/10.1016\/j.jaci.2009.02.016.","journal-title":"J Allergy Clin Immunol."},{"key":"629_CR9","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/317465","author":"AD Yalcin","year":"2015","unstructured":"Yalcin AD. Advances in anti-IgE therapy. Biomed Res Int. 2015. https:\/\/doi.org\/10.1155\/2015\/317465.","journal-title":"Biomed Res Int."},{"issue":"6","key":"629_CR10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.anai.2013.04.011","volume":"110","author":"DJ Maselli","year":"2013","unstructured":"Maselli DJ, Singh H, Diaz J, Peters JI. Efficacy of omalizumab in asthmatic patients with IgE levels above 700 IU\/mL: a retrospective study. Ann Allergy Asthma Immunol. 2013;110(6):457\u201361. https:\/\/doi.org\/10.1016\/j.anai.2013.04.011.","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Allergy, Asthma &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-021-00629-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13223-021-00629-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-021-00629-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T12:14:31Z","timestamp":1639052071000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacijournal.biomedcentral.com\/articles\/10.1186\/s13223-021-00629-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["629"],"URL":"https:\/\/doi.org\/10.1186\/s13223-021-00629-z","relation":{},"ISSN":["1710-1492"],"issn-type":[{"value":"1710-1492","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"17 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Patient\u2019s written consent to publication of information about them was obtained and is available upon request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"128"}}